AVROBIO IncNASDAQ:AVRO
- LAST PRICE1.2150
- TODAY'S CHANGE (%)-0.0250 (-2.0161%)
- Bid / Lots1.2000/ 2
- Ask / Lots1.2200/ 2
- Open / Previous Close1.2270 / 1.2400
- Day Range
- 52 Week Range
- Volume33,166
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AVRO |
|---|---|---|
| 10:44 ET | 2000 | 1.2214 |
| 10:48 ET | 200 | 1.22 |
| 10:55 ET | 400 | 1.22 |
| 11:06 ET | 100 | 1.22 |
| 11:24 ET | 100 | 1.22 |
| 11:47 ET | 399 | 1.22 |
| 12:27 ET | 145 | 1.22 |
| 12:34 ET | 100 | 1.22 |
| 12:39 ET | 10910 | 1.22 |
| 12:43 ET | 425 | 1.23 |
| 12:52 ET | 300 | 1.23 |
| 12:57 ET | 100 | 1.22 |
| 12:59 ET | 100 | 1.22 |
| 01:01 ET | 300 | 1.22 |
| 01:03 ET | 300 | 1.215 |
| 01:06 ET | 100 | 1.215 |
| 01:19 ET | 600 | 1.21 |
| 01:21 ET | 900 | 1.21 |
| 01:28 ET | 100 | 1.215 |
| 01:30 ET | 100 | 1.22 |
| 01:32 ET | 100 | 1.215 |
| 01:33 ET | 100 | 1.2104 |
| 01:55 ET | 348 | 1.21 |
| 02:08 ET | 100 | 1.215 |
| 02:15 ET | 3672 | 1.21 |
| 02:20 ET | 100 | 1.2 |
| 02:24 ET | 100 | 1.21 |
| 02:26 ET | 100 | 1.205 |
| 02:29 ET | 100 | 1.2 |
| 02:36 ET | 900 | 1.21 |
| 02:40 ET | 100 | 1.205 |
| 02:44 ET | 100 | 1.2 |
| 02:47 ET | 1800 | 1.195 |
| 02:51 ET | 300 | 1.195 |
| 02:54 ET | 3469 | 1.195 |
| 02:56 ET | 505 | 1.215 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
AVROBIO Inc | 55.6M | 4.4x | --- |
Oncolytics Biotech Inc | 78.4M | -3.5x | --- |
Checkpoint Therapeutics Inc | 57.1M | -0.5x | --- |
Immix Biopharma Inc | 58.3M | -2.5x | --- |
Reneo Pharmaceuticals Inc | 58.8M | -0.7x | --- |
Vaxxinity Inc | 58.9M | -1.0x | --- |
Company Information
AVROBIO, Inc. is a gene therapy company. The Company is focused on developing potentially curative hematopoietic stem cells (HSC) gene therapies to treat patients with rare diseases following a single dose treatment regimen. The gene therapies that the Company is engaged in developing employ HSCs that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company's development focus has been on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies (ERTs). Its pipeline is comprised of three HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-03 for the treatment of Pompe disease, and AVR-RD-01 for the treatment of Fabry disease.
Contact Information
- Headquarters
- 100 TECHNOLOGY SQUARE, 6TH FLOORCAMBRIDGE, MA, United States 02139
- Phone
- 617-914-8420
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Bruce Booth
- President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer
- Erik Ostrowski
- Chief Technology Officer
- Azadeh Golipour
- Chief Business Officer
- Deanna Petersen
- Chief Medical Officer
- Essra Ridha
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $55.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $0.28 |
Book Value | $2.12 |
P/E Ratio | 4.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | 4.4x |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
